Breaking News

Celerion Expands Into Singapore

June 4, 2014

Appoints Dr. Chong to head operations

Celerion is expanding its presence in Singapore and has appointed Dr. Chew Lan Chong, MBBS, MRCS, MSc, as executive director of Medical Research. Dr. Chong has 10 years of operational experience leading clinical pharmacology units and has conducted more than 130 early clinical studies at organizations including Pfizer and Lilly in Singapore.  
Dr. Chong will lead Celerion’s business operations in Singapore, provide medical and scientific expertise and collaborate with partner early clinical research units to conduct complex early clinical pharmacology studies in accordance with global standards.
Celerion also recently expanded into South Korea, opening clinical operations at Seoul National University Hospital (SNUH) Clinical Trial Center, and entered a collaboration with the Korean Drug Development Fund (KDDF).
These expansions will provide access to Asian patients and healthy participants for early clinical research studies, including oncology, hepatitis B, cardiovascular, diabetes, arthritis, osteoporosis, pain, psychiatric conditions, Alzheimer’s disease, Parkinson’s disease, asthma and COPD. In addition, Celerion’s partners will provide pharmacogenetics and ethnic bridging studies in Asian populations.
“We are delighted to continue to build a strong footprint in Asia with our new office in Singapore, headed up by Chew Lan,” said Frederick Pritchard Ph.D., vice president of Global Drug Development at Celerion. “The continued expansion in Asia demonstrates Celerion’s commitment to providing clients innovative solutions to conduct patient studies. Dr. Chong’s academic qualifications and practical experience make her the perfect choice to head up our operations in Singapore conducting the types of innovative and challenging studies involved in translational and experimental medicine.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important